GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment.

Raiter A, Lipovetzki J, Lubin I, Yerushalmi R

Open source

DOI
10.1186/s12885-020-06835-z
Published
2020 Apr 19
Container
BMC cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12885-020-06835-z,
  title = {GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment.},
  author = {Raiter A and Lipovetzki J and Lubin I and Yerushalmi R},
  year = {2020},
  journal = {BMC cancer},
  doi = {10.1186/s12885-020-06835-z},
  url = {https://doi.org/10.1186/s12885-020-06835-z}
}

RIS

TY  - JOUR
TI  - GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment.
AU  - Raiter A
AU  - Lipovetzki J
AU  - Lubin I
AU  - Yerushalmi R
PY  - 2020
JO  - BMC cancer
DO  - 10.1186/s12885-020-06835-z
UR  - https://doi.org/10.1186/s12885-020-06835-z
ER  - 

APA

A, R., J, L., I, L., & R, Y. (2020). GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment.. BMC cancer. https://doi.org/10.1186/s12885-020-06835-z

Source records